Back to Report Store Home

Frontier Pharma: Breast Cancer – First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast Cancer

  • Published: Jul-2018
  • Report Code: GBIHC477MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Breast Cancer, Global, Innovation Trends in Product Approvals Across the Pharmaceutical Market, 1987–2014 7

Figure 2: Breast Cancer, Global, Post-Marketing-Approval Sales Performance of First-in-Class Products Across the Pharmaceutical Industry ($m), 2006–2013 8

Figure 3: Breast Cancer, Global, Treatment Algorithm for Cancer Diagnosed at Stages I to III, 2018 21

Figure 4: Breast Cancer, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV, 2018 22

Figure 5: Breast Cancer, Global, Market by Molecule Type and Molecular Target, 2018 27

Figure 6: Breast Cancer, Global, Pipeline Size by Therapy Area, 2018 29

Figure 7: Breast Cancer, Global, Pipeline by Stage of Development and Molecule Type, 2018 30

Figure 8: Breast Cancer, Global, Pipeline by Molecular Target and Breakdown of Growth Factor Antagonist Molecular Target Class, 2018 31

Figure 9: Breast cancer, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2018 32

Figure 10: Breast Cancer, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2018 34

Figure 11: Breast Cancer, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2018 36

Figure 12: Breast Cancer, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2018 37

Figure 13: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 1) 38

Figure 14: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 2) 39

Figure 15: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 3) 40

Figure 16: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 4) 41

Figure 17: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 5) 42

Figure 18: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 6) 43

Figure 19: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 7) 44

Figure 20: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 8) 45

Figure 21: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 9) 46

Figure 22: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 10) 47

Figure 23: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 11) 48

Figure 24: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 12) 49

Figure 25: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 13) 50

Figure 26: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 14) 51

Figure 27: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 15) 52

Figure 28: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 16) 53

Figure 29: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 17) 54

Figure 30: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 18) 55

Figure 31: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 19) 56

Figure 32: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 20) 57

Figure 33: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 21) 58

Figure 34: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 22) 59

Figure 35: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 23) 60

Figure 36: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 24) 61

Figure 37: Breast Cancer, Global, First-in-Class Molecular Target Matrix Assessment for Breast Cancer, 2018 (part 1) 64

Figure 38: Breast Cancer, Global, First-in-Class Molecular Target Matrix Assessment for Breast Cancer, 2018 (part 2) 65

Figure 39: Breast Cancer, Global, First-in-Class Molecular Target Matrix Assessment for Breast Cancer, 2018 (part 3) 66

Figure 40: Breast Cancer, Global, First-in-Class Molecular Target Matrix Assessment for Breast Cancer, 2018 (part 4) 67

Figure 41: Breast Cancer, Global, First-in-Class Molecular Target Matrix Assessment for Breast Cancer, 2018 (part 5) 68

Figure 42: Breast Cancer, Global, First-in-Class Molecular Target Matrix Assessment for Breast Cancer, 2018 (part 6) 68

Figure 43: Breast Cancer, Global, First-in-Class Molecular Target Matrix Assessment for Breast Cancer, 2018 (part 7) 69

Figure 44: Breast Cancer, Global, Industry-Wide Licensing Deals by First-in-Class Status and Stage of Development, 2006–2015 83

Figure 45: Breast Cancer, Global, Industry-Wide Licensing Deals by First-in-Class Status, Deal Value, Upfront Payment Value and Stage of Development, 2006–2014 84

Figure 46: Breast Cancer, Global, Licensing Deals by Region, Value and Year, 2006–2018 86

Figure 47: Breast Cancer, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006–2018 87

Figure 48: Breast Cancer, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target Class, 2006–2018 88

Figure 49: Breast Cancer, Global, Licensing Deals with Disclosed Deal Values, 2006–2018 (part 1) 89

Figure 50: Breast Cancer, Global, Licensing Deals with Disclosed Deal Values, 2006–2018 (part 2) 90

Figure 51: Breast Cancer, Global, Licensing Deals with Disclosed Deal Values, 2006–2018 (part 3) 91

Figure 52: Breast Cancer, Global, Co-development Deals by Region, Value and Year, 2006–2018 92

Figure 53: Breast Cancer, Global, Number and Aggregate Deal Value of Co-development Deals by Stage of Development and Year, 2006–2018 93

Figure 54: Breast Cancer, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target Class, 2006–2018 94

Figure 55: Breast Cancer, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target Class, 2006–2018 95

Figure 56: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 1) 96

Figure 57: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 2) 97

Figure 58: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 3) 98

Figure 59: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 4) 99

Figure 60: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 5) 100

Figure 61: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 6) 101

Figure 62: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 7) 102

Figure 63: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 8) 103

Figure 64: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 9) 104

Figure 65: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 10) 104

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards